Obstetric and Gynecologic Imaging

Which Imaging Study Is Best for Suspected Ovarian Cancer Recurrence? An ACR-Guided Workflow

·
Which Imaging Study Is Best for Suspected Ovarian Cancer Recurrence? An ACR-Guided Workflow

A 58-year-old woman with a history of Stage III high-grade serous ovarian cancer, who completed primary debulking surgery and chemotherapy 18 months ago, presents to her gynecologic oncologist for follow-up. Her CA-125 level, which had normalized post-treatment, has now risen on two consecutive checks. She also reports new, vague abdominal bloating and fatigue. The clinical suspicion for recurrent disease is high, and the immediate question is which imaging study to order to confirm and map the extent of disease. This article provides a detailed workflow for this specific scenario, guiding the choice of imaging based on the American College of Radiology (ACR) Appropriateness Criteria. For this presentation, `CT abdomen and pelvis with IV contrast` is rated Usually Appropriate.

Who Fits This Clinical Scenario for Suspected Ovarian Cancer Recurrence?

This guidance is for an adult patient with a previously diagnosed and treated ovarian cancer who now presents with signs, symptoms, or laboratory findings suggestive of recurrence. This is a distinct clinical situation that requires a specific imaging strategy focused on detecting disease that is often diffuse and low-volume.

Inclusion criteria for this workflow:

  • A confirmed history of ovarian, fallopian tube, or primary peritoneal cancer.
  • Completion of primary treatment (e.g., surgery, chemotherapy).
  • New clinical suspicion of recurrence, which may be triggered by:
    • Rising serum tumor markers (e.g., CA-125).
    • New or worsening symptoms such as abdominal pain, bloating, early satiety, or a palpable mass.
    • Equivocal findings on a physical examination.

It is critical to distinguish this scenario from similar, but distinct, clinical situations that follow different imaging pathways. This workflow does not apply to:

  • Initial Pretreatment Staging: The imaging workup for a newly diagnosed, untreated ovarian mass is different.
  • Posttreatment Response Evaluation: This involves imaging performed at planned intervals during or immediately after a course of therapy to assess its effectiveness.
  • Routine Asymptomatic Surveillance: This refers to scheduled imaging in a patient with no symptoms or biochemical evidence of recurrence. The role and modality of imaging in this context are debated and follow a separate set of recommendations.

What Diagnoses Are You Working Up When Suspecting Ovarian Cancer Recurrence?

When ordering imaging for suspected ovarian cancer recurrence, the primary goal is to confirm the presence of disease, define its extent, and identify sites that may be amenable to treatment. The differential diagnosis in this setting is focused and driven by the known patterns of disease spread.

Peritoneal Carcinomatosis
This is the most common pattern of recurrence for epithelial ovarian cancer. Malignant cells spread throughout the peritoneal cavity, forming nodules or plaques on the surfaces of organs and the peritoneum itself. Key areas to evaluate include the omentum (leading to “omental caking”), paracolic gutters, diaphragm, and bowel serosa. Widespread peritoneal disease can also lead to the development of malignant ascites.

Nodal Metastases
Recurrence can manifest as metastatic involvement of lymph nodes. The most common sites are the pelvic and para-aortic lymph node chains, which represent the primary lymphatic drainage pathways. However, disease can also appear in inguinal, mesenteric, or even distant nodes like those in the chest.

Parenchymal Organ Metastases
While less common than peritoneal or nodal disease, ovarian cancer can recur within solid organs. The liver and spleen are the most frequent sites of intra-abdominal parenchymal recurrence. Distant metastases to the lungs, pleura, or bone can also occur and must be evaluated, especially if a patient presents with corresponding symptoms.

Benign Post-Treatment Changes
A crucial part of the diagnostic workup is differentiating true recurrence from benign changes related to prior surgery and therapy. These can include post-surgical adhesions, fibrosis, scarring, benign fluid collections (lymphoceles), or inflammatory changes that can mimic malignancy on imaging and sometimes cause similar symptoms.

Why Is CT of the Abdomen and Pelvis with IV Contrast Usually Appropriate for Suspected Recurrence?

The ACR rates `CT abdomen and pelvis with IV contrast` as Usually Appropriate for evaluating suspected ovarian cancer recurrence because it provides a rapid, widely available, and comprehensive assessment of the abdomen and pelvis. Its high spatial resolution is excellent for identifying the key patterns of recurrence.

Intravenous contrast is essential. It causes enhancing tumor implants to stand out against adjacent non-enhancing structures like unopacified bowel loops or ascites. This significantly increases the sensitivity for detecting small peritoneal nodules, omental caking, and subtle serosal disease that would be invisible on non-contrast imaging. CT is also highly effective at identifying enlarged metastatic lymph nodes and parenchymal metastases in the liver and spleen.

For a complete evaluation, a `CT chest with IV contrast` is also rated Usually Appropriate and is almost always performed at the same time as the abdomen/pelvis scan. This allows for the detection of pleural effusions, pleural-based metastases, lung nodules, and mediastinal or supraclavicular lymphadenopathy in a single imaging session.

Why are other studies rated lower for this initial workup?

  • MRI abdomen and pelvis without and with IV contrast is rated May be appropriate. While MRI offers excellent soft-tissue contrast and avoids ionizing radiation, it is generally more time-consuming, less accessible, and can be more susceptible to motion artifact from breathing and bowel peristalsis. This can make it harder to detect the tiny, diffuse peritoneal implants characteristic of ovarian cancer recurrence. MRI’s primary role is often as a problem-solving tool, for instance, to better characterize an indeterminate liver lesion seen on CT or for patients with a severe allergy to iodinated contrast.
  • Ultrasound (transabdominal or transvaginal) is rated Usually not appropriate. While ultrasound is a primary tool for evaluating an initial adnexal mass, its utility in the recurrence setting is very limited. It cannot adequately survey the entire peritoneal cavity, omentum, or retroperitoneal lymph nodes, and its sensitivity for detecting small-volume peritoneal disease is low.

The radiation dose for a CT of the abdomen and pelvis is moderate (ACR RRL ☢☢☢, 1-10 mSv). This risk is generally considered acceptable given the high clinical stakes of missing a treatable recurrence. Once you’ve decided on CT, our protocol guide covers the technique, contrast, and reading principles: CT Chest/Abdomen/Pelvis with IV Contrast.

What Is the Downstream Workflow After a CT for Suspected Ovarian Cancer Recurrence?

The results of the CT scan directly inform the next steps in management, creating a clear decision tree for the clinical team.

If the CT is positive for recurrent disease:
A positive scan confirms the clinical suspicion and provides a roadmap of the disease burden. The location and volume of disease will guide the gynecologic oncology team’s recommendations. If disease appears to be focal and completely resectable, the patient may be a candidate for secondary cytoreductive surgery. If the disease is widespread and unresectable, the next step is typically a change in systemic therapy, such as starting a new line of chemotherapy or targeted agents (e.g., PARP inhibitors). In some cases, a biopsy of a recurrent lesion may be performed to confirm histology and obtain tissue for molecular testing to guide therapy.

If the CT is negative:
A negative CT in a patient with a high clinical suspicion (e.g., a significantly rising CA-125) presents a diagnostic challenge. This may indicate microscopic or low-volume disease below the resolution of CT. In this situation, the next step is often to order a more sensitive imaging study. `FDG-PET/CT skull base to mid-thigh` is also rated Usually Appropriate for this scenario and is particularly valuable in the setting of a negative CT, as it can detect small, metabolically active tumor deposits that are not visible morphologically.

If the CT is indeterminate:
Occasionally, CT may reveal findings that are equivocal, such as subtle soft tissue thickening or a non-specific fluid collection. In these cases, short-term follow-up imaging may be appropriate. Alternatively, a problem-solving modality like MRI or a functional study like FDG-PET/CT can be used to further characterize the indeterminate finding and determine if it represents recurrence or benign post-treatment change.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected ovarian cancer recurrence requires careful attention to detail to avoid common errors.

  • Ordering without IV contrast: A non-contrast CT has severely limited sensitivity for peritoneal disease and is often non-diagnostic in this setting. Always specify “with IV contrast” unless there is a strong contraindication.
  • Ignoring the chest: Ovarian cancer frequently metastasizes to the pleura and lungs. Failing to image the chest concurrently with the abdomen and pelvis can miss a significant portion of a patient’s disease burden.
  • Over-reliance on a negative CT: If clinical suspicion (especially a rising CA-125) is high, a negative CT does not definitively rule out recurrence. This is a key trigger to consider escalating to a more sensitive study like FDG-PET/CT.
  • Misinterpreting post-surgical changes: Benign fibrosis, adhesions, and lymphoceles can mimic recurrent disease. Comparing with prior scans is crucial, and if uncertainty persists, consultation with a radiologist specializing in gynecologic oncology imaging is recommended.

If the imaging findings are complex or discordant with the clinical picture, a discussion at a multidisciplinary tumor board is the best next step.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all clinical situations related to ovarian cancer, from initial diagnosis to surveillance, please refer to our parent topic hub article. For tools to help with ordering, protocoling, and discussing studies with patients, see the resources below.

Frequently Asked Questions

Why is FDG-PET/CT also rated ‘Usually Appropriate’ for suspected ovarian cancer recurrence?

FDG-PET/CT is also rated ‘Usually Appropriate’ because it combines functional information (metabolic activity) with anatomic information (CT). It is particularly sensitive for detecting small-volume, metabolically active disease that may be missed on a standard contrast-enhanced CT. It is often used as the next step when a conventional CT is negative but clinical suspicion for recurrence remains high due to rising tumor markers like CA-125.

What if my patient has a severe allergy to iodinated CT contrast?

For a patient with a severe allergy to iodinated contrast or significant renal impairment, `MRI abdomen and pelvis without and with IV contrast` using a gadolinium-based agent is a suitable alternative and is rated ‘May be appropriate’. While potentially less sensitive for tiny peritoneal implants than CT, it avoids iodinated contrast and provides excellent soft-tissue characterization, especially for liver or adnexal lesions.

Is there a role for tumor markers like CA-125 instead of imaging?

Serum CA-125 is a critical tool for monitoring, and a rising level is often the first sign of recurrence. However, it does not provide information on the location or extent of the disease. Imaging is necessary to confirm recurrence, map the disease burden, and plan treatment, whether that be surgery or systemic therapy. Imaging is complementary to, not a replacement for, tumor marker surveillance.

How does this imaging strategy differ from routine surveillance in an asymptomatic patient?

This workflow is for patients with a specific clinical suspicion of recurrence (symptoms or rising markers). The role of routine imaging for surveillance in asymptomatic patients with normal tumor markers is more controversial. Some guidelines recommend against routine surveillance imaging due to a lack of proven survival benefit and the potential for false positives. The imaging strategy for an asymptomatic patient is covered under a different ACR scenario.

Should oral contrast be used for the CT scan?

Yes, the use of oral contrast is generally recommended. It helps to opacify the bowel loops, making it easier to distinguish them from adjacent structures like mesenteric masses, lymph nodes, or peritoneal implants. Both positive (iodinated) and neutral (e.g., water or Volumen) oral contrast agents can be used depending on institutional protocol.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026